First-in-Class Diabetes Drug Approved

Share this article:

The FDA has approved Invokana (canagliflozin), a first-in-class medication that helps to improve glycemic control in adults with type 2 diabetes.

Manufactured by Janssen Pharmaceuticals based in Raritan, N.J., canagliflozin is a sodium-glucose co-transporter 2 inhibitor that blocks reabsorption of glucose in the kidney, increases glucose excretion, and lowers blood glucose levels.

The drug was studied in combination with other treatments for type 2 diabetes, including metformin, sulfonylurea, pioglitazone, and insulin across nine clinical trials that included 10,285 patients. From the trials, researchers noted an improvement in hemoglobin A1c levels and fasting plasma glucose levels in addition to reduced body weight and systolic blood pressure.

Share this article:
You must be a registered member of RUN to post a comment.

More in Diabetes

Two-Year Weight Loss Reduces Diabetes Risk

Two-Year Weight Loss Reduces Diabetes Risk

Weight cycling linked to increased diabetes risk, even after adjustment for baseline weight.

Whey Protein Lowers Glucose in Diabetics

Whey Protein Lowers Glucose in Diabetics

Whey pre-load linked to reduction in glucose levels, improved early insulin response, GLP-1 levels.

FDA Okays Rapid-Acting Inhaled Insulin

FDA Okays Rapid-Acting Inhaled Insulin

Afrezza is administered at the start of each meal or within 20 minutes after starting a meal.